Revenue ($USD) : $366,379,000
R&D spend : $34,886,000
Employees : 797
Fiscal year end : 12/31/2023
CEO : Raymond Cohen

www.axonics.com

Axonics develops neuromodulation systems for treating urinary and bowel dysfunction. Its fourth-generation R20 rechargeable sacral neuromodulation (SNM) system received FDA approval around the start of 2023, and Axonics launched its recharge-free F15 SNM system in 2022. The company also offers the Bulkamid urethral bulking agent for stress urinary incontinence symptoms. Axonics’ future remains in limbo as Boston Scientific announced its intent to buy the company in January 2024, but the deal’s timeline has been pushed back due to scrutiny from the U.S. Federal Trade Commission. –SW